HC Wainwright & Co. Reiterates Buy on Biogen, Maintains $325 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on Biogen (NASDAQ:BIIB) and maintained a $325 price target.
June 12, 2023 | 10:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on Biogen and maintained a $325 price target.
The reiteration of a Buy rating and maintenance of a $325 price target by HC Wainwright & Co. analyst Andrew Fein indicates a positive outlook for Biogen's stock. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's performance and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100